Cargando…

The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service

BACKGROUND: The internet portal http://www.brustkrebs-studien.de (BKS) was launched in 2000 by the German Society of Senology (DGS) and the Baden-Württemberg Institute for Women's Health (IFG) to provide expert-written information on breast cancer online and to encourage and facilitate the part...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallwiener, Markus, Wallwiener, Christian W, Brucker, Sara Y, Hartkopf, Andreas D, Fehm, Tanja N, Kansy, Julia K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016291/
https://www.ncbi.nlm.nih.gov/pubmed/21126358
http://dx.doi.org/10.1186/1471-2407-10-663
_version_ 1782195713189347328
author Wallwiener, Markus
Wallwiener, Christian W
Brucker, Sara Y
Hartkopf, Andreas D
Fehm, Tanja N
Kansy, Julia K
author_facet Wallwiener, Markus
Wallwiener, Christian W
Brucker, Sara Y
Hartkopf, Andreas D
Fehm, Tanja N
Kansy, Julia K
author_sort Wallwiener, Markus
collection PubMed
description BACKGROUND: The internet portal http://www.brustkrebs-studien.de (BKS) was launched in 2000 by the German Society of Senology (DGS) and the Baden-Württemberg Institute for Women's Health (IFG) to provide expert-written information on breast cancer online and to encourage and facilitate the participation of breast cancer patients in clinical trials. We describe the development of BKS and its applications, and report on website statistics and user acceptance. METHODS: Existing registries, including ClinicalTrials.gov, were analysed before we designed BKS, which combines a trial registry, a knowledge portal, and an online second opinion service. An advisory board guided the process. Log files and patient enquiries for trial participation and second opinions were analysed. A two-week user satisfaction survey was conducted online. RESULTS: During 10/2005-06/2010, the portal attracted 702,655 visitors, generating 15,507,454 page views. By 06/2010, the website's active scientific community consisted of 189 investigators and physicians, and the registry covered 163 clinical trial protocols. In 2009, 143 patients requested trial enrolment and 119 sought second opinions or individual treatment advice from the expert panel. During the two-week survey in 2008, 5,702 BKS visitors submitted 507 evaluable questionnaires. Portal acceptance was high. Respondents trusted information correctness (80%), welcomed self-matching to clinical trials (79%) and planned to use the portal in the future (76%) and recommend it to others (81%). CONCLUSIONS: BKS is an established and trusted breast cancer information platform offering up-to-date resources and protocols to the growing physician and patient community to encourage participation in clinical trials. Further studies are needed to assess potential increases in trial enrolment by eligibility matching services.
format Text
id pubmed-3016291
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30162912011-01-06 The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service Wallwiener, Markus Wallwiener, Christian W Brucker, Sara Y Hartkopf, Andreas D Fehm, Tanja N Kansy, Julia K BMC Cancer Research Article BACKGROUND: The internet portal http://www.brustkrebs-studien.de (BKS) was launched in 2000 by the German Society of Senology (DGS) and the Baden-Württemberg Institute for Women's Health (IFG) to provide expert-written information on breast cancer online and to encourage and facilitate the participation of breast cancer patients in clinical trials. We describe the development of BKS and its applications, and report on website statistics and user acceptance. METHODS: Existing registries, including ClinicalTrials.gov, were analysed before we designed BKS, which combines a trial registry, a knowledge portal, and an online second opinion service. An advisory board guided the process. Log files and patient enquiries for trial participation and second opinions were analysed. A two-week user satisfaction survey was conducted online. RESULTS: During 10/2005-06/2010, the portal attracted 702,655 visitors, generating 15,507,454 page views. By 06/2010, the website's active scientific community consisted of 189 investigators and physicians, and the registry covered 163 clinical trial protocols. In 2009, 143 patients requested trial enrolment and 119 sought second opinions or individual treatment advice from the expert panel. During the two-week survey in 2008, 5,702 BKS visitors submitted 507 evaluable questionnaires. Portal acceptance was high. Respondents trusted information correctness (80%), welcomed self-matching to clinical trials (79%) and planned to use the portal in the future (76%) and recommend it to others (81%). CONCLUSIONS: BKS is an established and trusted breast cancer information platform offering up-to-date resources and protocols to the growing physician and patient community to encourage participation in clinical trials. Further studies are needed to assess potential increases in trial enrolment by eligibility matching services. BioMed Central 2010-12-02 /pmc/articles/PMC3016291/ /pubmed/21126358 http://dx.doi.org/10.1186/1471-2407-10-663 Text en Copyright ©2010 Wallwiener et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wallwiener, Markus
Wallwiener, Christian W
Brucker, Sara Y
Hartkopf, Andreas D
Fehm, Tanja N
Kansy, Julia K
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title_full The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title_fullStr The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title_full_unstemmed The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title_short The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
title_sort brustkrebs-studien.de website for breast cancer patients: user acceptance of a german internet portal offering information on the disease and treatment options, and a clinical trials matching service
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016291/
https://www.ncbi.nlm.nih.gov/pubmed/21126358
http://dx.doi.org/10.1186/1471-2407-10-663
work_keys_str_mv AT wallwienermarkus thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT wallwienerchristianw thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT bruckersaray thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT hartkopfandreasd thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT fehmtanjan thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT kansyjuliak thebrustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT wallwienermarkus brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT wallwienerchristianw brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT bruckersaray brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT hartkopfandreasd brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT fehmtanjan brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice
AT kansyjuliak brustkrebsstudiendewebsiteforbreastcancerpatientsuseracceptanceofagermaninternetportalofferinginformationonthediseaseandtreatmentoptionsandaclinicaltrialsmatchingservice